Key clinical point: Prior antibiotic exposure may hinder the efficacy of checkpoint inhibitors.
Major finding: Median overall survival was 2 months with prior antibiotic exposure versus 26 months without.
Study details: A prospective, observational study of 196 patients with various cancers treated with immune checkpoint inhibitors.
Disclosures: The study was internally supported. Dr. Pinato reported receiving grant funding from Merck and Bristol-Myers Squibb unrelated to the study, as well as honoraria from ViiV Healthcare.
Pinato DJ et al. ASCO-SITC,.
This Week's Must Reads
Must Reads in Head & Neck Cancers
Monalizumab + cetuximab is active in advanced SCC of the head and neck, Cohen R et al. SITC 2018, Abstract 051
Overall survival lower with cetuximab in oropharyngeal cancer, Mehanna H et al. ESMO 2018, Abstract LBA9_PR
Head and neck cancer therapy toxicities greater in women, Cristina V et al. JAMA Oncol. 2018 May 24. doi: 10.1001/jamaoncol.2018.1080.